



# Corporate Presentation

November 2021

# Forward looking statements

This presentation contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this presentation which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. These forward-looking statements generally can be identified by phrases such as Q BioMed, Inc. ("QBIO") or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar importance.

Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in these forward-looking statements which are made as of the date of this presentation, and we assume no obligation to update any forward-looking statements. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our public filings. Although we believe that any beliefs, plans, expectations and intentions contained in this presentation are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should review all of the information set forth herein and should also understand the risk factors and the inherent uncertainties associated with new business opportunities and development stage. Any use of this information for any purpose other than in connection with the consideration of an investment in Q BioMed Inc. may subject the user to criminal and civil liability.

This presentation does not constitute an offer to sell any securities or the solicitation of an offer to sell any securities by Q BioMed Inc.



# Corporate Introduction





Rapid biotech growth has created a plethora of scientific assets. And with so many assets being developed so quickly, things fall by the wayside... even if they shouldn't.

**That's the cost of innovation.**



At Q BioMed, we find  
undiscovered or undervalued  
biomedical technologies and  
maximize their potential yield.

**That's the opportunity**

Q Nuclear Medicine

**strontium<sup>89</sup>**  
Strontium Chloride Sr-89  
Injection, USP

**UTTROSIDE-B**

Mannin  
Tie2 Platform

**MAN 01**

**MAN 11**

**GDF15**

Q Rare Disease

**QBM-001**

Infectious & Vascular  
Diseases

**MAN 19**

**MAN 12**

This is our growing portfolio  
of high-value assets



Drug Candidate | Preclinical | Phase 1 | Phase 2 | Phase 3 | Approval

**strontium<sup>89</sup>**  
Strontium Chloride Sr-89  
Injection, USP

Radiopharmaceutical for metastatic bone cancer pain

**QBM-001**

Pediatric non-verbal Autism Spectrum Disorder

**UTTROSIDE-B**

Chemotherapeutic for liver cancer

**MAN 19**

Infectious diseases (including COVID-19)

**MAN 01**

Topical eyedrops for glaucoma

**MAN 11**

Biologic Long Lasting Injection for Glaucoma

**MAN 12**

Acute Kidney disease



Our leading commercial asset is

# strontium<sup>89</sup>

Strontium Chloride Sr-89  
Injection, USP

## MILESTONES:

- CMO received final FDA approval Nov, 2019
- Marketing & sales commenced Q2, 2020
- National Distribution Jubilant Draximage June 2020
- CMS Medicare Approval Jan 2021
- FFS - Federal Supply Contract March 2021
- VA - DoD Sales Force Deployed June 2021
- Commercial Partnership Announced - Nov 2021
- International Distribution Agreements 2021
- Available in EU and Rest of World through Named Patient Program
- Now THE ONLY Radionuclide available in USA for pain palliation in metastatic cancer bone pain!





# Bone mets - a worldwide market opportunity



---

**10 Million**


The number of people worldwide that experience daily pain due to malignant disease<sup>1</sup>



---

**5,000**

The projected number of annual Sr-89 doses based on 0.05% of the market - 5,000 patients at only 1 dose = \$50M



---


**8.4 Percent**

The approximate CAGR at which the global bone metastasis market is expected to grow<sup>2</sup>


1. World Health Organization. Cancer pain relief and palliative care. World Health Organ Tech Rep Ser. 1990;804:7-73

2. Medgadget

# Strontium89 offers lasting pain relief and fewer new pain sites



Pre-treatment



5 months post-treatment

# Potential for therapeutic indication

A decrease of >50% in serum PSAV was observed in 37% of patients with hormone-refractory prostate cancer after treatment with METASTRON™<sup>6</sup>

In a multicenter, RCT involving 126 patients with mCRPC, all of whom received external beam radiotherapy, additional treatment with METASTRON™ delayed disease progression [Porter\_1993]

Many patients show a reduced intensity of hot spots on bone scan compared with pretreatment images.<sup>11,16</sup> suggesting a possible tumoricidal effect from METASTRON™

Case reports describe regression of osteoblastic and osteolytic bone metastases in patients with breast cancer and hepatocellular carcinoma after treatment with METASTRON™<sup>16,17</sup>

In the recent TRAPEZE randomized controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid (ZA), METASTRON, or both in men with bony metastatic castration-refractory prostate cancer, METASTRON was shown to improve CPFS, while ZA did not.

*A potential survival benefit associated with the use of Sr-89 has been reported, and future randomized, placebo-controlled studies may confirm the effect of Sr-89 on overall survival*



## Mannin Research Platform

### MILESTONES:



Platform Technology:

**Tie-2 Mechanism of Action**

Potential Therapeutic Indications:

**Infectious Diseases:**  
*Acute Respiratory Distress Syndrome  
Covid19, SARS, Influenza, Pneumonia, Sepsis,  
H1N1, Other Pandemics*

**Primary Open-Angle Glaucoma**

**Kidney Disease:**  
**Acute Kidney Injury, Cystic Kidney Disease**

Addressable Market:

**\$Bs in multiple therapeutic areas**

Stage:

**Preclinical**






# MAN-19


Pharmaceutical: **MAN-19 Biologic**

Condition: **COVID-19**

Addressable Market: **Global Infectious Diseases**

Technology Partner: 

Stage: **Preclinical (Phase 1 Q1-2022)**



# MAN-19 Stabilizes Endothelial Vasculature, Which May Have Beneficial Effects in Lung Injury and ARDS Associated With COVID-19

The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection

Stéphanie Pons<sup>1,2</sup>, Sofiane Fodil<sup>3</sup>, Elie Azoulay<sup>3</sup> and Lara Zafrani<sup>1,2\*</sup>

EDITORIAL



Covid-19, Angiogenesis, and ARDS Endotypes

Lida Hariri, M.D., Ph.D., and C. Corey Hardin, M.D., Ph.D.

THE NEW ENGLAND JOURNAL OF MEDICINE

ORIGINAL ARTICLE

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Maximilian Ackermann, M.D., Stijn E. Verleden, Ph.D., Mark Kuehnel, Ph.D., Axel Haverich, M.D., Tobias Welte, M.D., Florian Laenger, M.D., Arno Vanstapel, Ph.D., Christopher Werlein, M.D., Helge Stark, Ph.D., Alexandar Tzankov, M.D., William W. Li, M.D., Vincent W. Li, M.D., Steven I. Mentzer, M.D., and Danny Ionişik, M.D.

Plasma Angiopoietin-2 Predicts the Onset of Acute Lung Injury in Critically Ill Patients

Ashish Agrawal<sup>1</sup>, Michael A. Matthay<sup>2,3,4</sup>, Kirsten N. Kangelaris<sup>1</sup>, John Stein<sup>5</sup>, Jeffrey C. Chu<sup>1</sup>, Brandon M. Imp<sup>1</sup>, Alfredo Cortez<sup>2</sup>, Jason Abbott<sup>1</sup>, Kathleen D. Liu<sup>2,3</sup>, and Carolyn S. Calfee<sup>2,3</sup>  
School of Medicine, <sup>2</sup>Department of Anesthesia, <sup>3</sup>Department of Medicine, <sup>4</sup>Cardiovascular Research Institute, and <sup>5</sup>Department of Emergency Medicine, Brigham Young University, Salt Lake City, Utah

MAN-19 is a first-in-class biologic treatment for COVID-19 patients, designed to ameliorate virus-induced pneumonia, sepsis and ARDS, decrease need of a ventilator, and reduce mortality rate. Half of deaths from COVID-19 related to vascular endothelial complications.

MAN-19 reduces vascular leakage, inflammation and coagulation by restoring vascular endothelial barrier integrity - a first endothelial host-directed solution to COVID-19.

Reducing endothelial permeability and vascular leakage in lung improves survival from severe influenza, supporting the host-directed therapeutic target for COVID-19 and other viruses likely to emerge in the future.

Potential in other viral infections and diseases, including: viral hemorrhagic fevers (Ebola, Dengue and Hantavirus), sepsis, severe influenza, malaria, anthrax, chronic mycobacterial infection, and corona viruses such as COVID-19.

# COVID-19 Clinical Program Early 2022

- Mannin received up to \$7.7 million in Europe, which will fund 65 percent of every dollar incurred to advance a portfolio of therapeutic assets for vascular diseases currently in development including: COVID-19, other infectious diseases such as influenza, cardiovascular diseases, acute kidney diseases.
- Rapidly accelerating the time to the first clinical milestone for MAN-19. Supported by the Canadian government - \$3 Million grant 2020. Additional \$100M applied for in non-dilutive funding.
- A GMP production contract has been initiated for MAN-19.
- An Investigational New Drug (IND) application (or similar clinical trial proposal) to regulators are planned for early 2022.
- MAN-19 therapeutic is virus-agnostic, which makes it relevant to other viral diseases today like influenza and future viral pandemic outbreaks.
- Therefore, a successful infectious disease application in COVID-19 would position MAN-19 very well as a potential government stockpile drug for inevitable future pandemics.
- Furthermore, a successful proof-of-concept clinical trial with MAN-19 in COVID-19 patients would provide the clinical dataset to quickly support the development of therapeutics for other vascular diseases such as sepsis, acute kidney injury, and of course glaucoma. All of these are very large markets with significant potential.



# MAN-01

Pharmaceutical: **MAN-01 Topical Drops**

Condition: **Primary Open-Angle Glaucoma**

Addressable Market: **60 million patients worldwide**

Technology Partner: 

Stage: **Preclinical**







# GDF15

Biomarker & Companion  
Diagnostic:

**GDF15**

Condition:

**Monitoring Glaucomatous Neurodegeneration**

Addressable  
Market:

**60 million patients**

Technology  
Partner:

**Washington University in St. Louis**

Stage:

**Preclinical Development of Diagnostic Kit;  
Clinical Trials using GDF15 as biomarker**



# Rare Disease Assets





# UTTROSIDE-B

Chemotherapy: **UTTROCIDE-B**

Condition: **Liver Cancer**

Addressable Market: **700,000 diagnoses/year**

Technology Partner: **Oklahoma Medical Research Foundation**

Stage: **Preclinical Testing Underway  
FDA IND Filing Expected 2022**

Milestone: **Orphan Drug Designation - Jan 2021**





**QBM-001**

Pharmaceutical: **QBM-001 sprinkle formulation**

Condition: **Rare Pediatric Non-Verbal Disorder**

Addressable Market: **50,000 cases worldwide  
15,000 in US alone**

Stage: **Pre-IND 505(b)2**

Pharmaceutical: **QBM-001 sprinkle formulation**

Market: **No Competition - \$5B Annual Revenue Potential**



# Capital Markets Overview and Management Outlook



# Capital Markets

Shares Outstanding	30,200,000
Warrants	10M
Inside Ownership	20%
Float	~ 20,000,000

Market Cap	\$26M
Current Price	\$0.50
Avg. Volume (30 day)	104,000
Year End	November 30

As of Nov, 2021



# What to Expect from Us in 2022

## Strontium89 Sales LAUNCH

US and Global Revenue Growth in 2021- 22 - target \$7-10M 2022 - \$12-20M 2023-24

Commercial Partnership w Eversana - Sales Team - Q1 2022

Post Marketing Study design to Expanded Use Q2 2022

International Market Access - Mid 2022

## MAN-19 Infectious Diseases – COVID-19 Clinical Trial

IND (or equivalent) Filing, Q1 2022

1 to 2-month Ph1 Clinical Trial Initiation Q2 2022

Potential Govt supply contracts and licensing revenue

Possible Emergency Approval End 2022

Govt Grants in excess of \$15M committed

\$100M in additional funding expected through commercialization

Very minimal capital required from Q

## Uttroside-B – Liver Cancer – Pancreatic Cancer

Complete preclinical - Prepare IND Q2 2022 - Final Tox H1 2022.

Potential Out-license or Clinical Trial Initiated End 2022

## MAN-01

Complete Molecule Optimization (Eye Drop) - Clinical Trial late 2022

Pharma Partnership opportunities 1H 2022

## Up-List to NASDAQ in Q1 2022

**Thank you**

